Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GALR3 | O60755 | 15/20 | 0.44 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.44 |
| ▸ | TTR | P02766 | 3/20 | 0.44 |
| ▸ | DRD5 | P21918 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12903538 | 1.00 | GALR3 (0.44) | GALR3HTR4TTRDRD5MEN1 | |
| SCHEMBL8089758 | 0.92 | GALR3 (0.46) | GALR3HTR4TTRDRD5MEN1 | |
| SCHEMBL8100044 | 0.87 | GALR3 (0.47) | GALR3HTR4TTRDRD5MEN1 | |
| SCHEMBL6905755 | 0.87 | GALR3 (0.58) | GALR3HTR4TTRDRD5MEN1 | |
| SCHEMBL8171379 | 0.87 | GALR3 (0.58) | GALR3HTR4TTRDRD5MEN1 | |
| SCHEMBL917768 | 0.86 | GALR3 (0.55) | GALR3HTR4TTRDRD5ADRA1A | |
| SCHEMBL916632 | 0.86 | GALR3 (0.52) | GALR3HTR4TTRDRD5ADRA1A | |
| SCHEMBL917766 | 0.86 | GALR3 (0.55) | GALR3HTR4TTRDRD5ADRA1A | |
| SCHEMBL916633 | 0.86 | GALR3 (0.52) | GALR3HTR4TTRDRD5ADRA1A | |
| SCHEMBL917993 | 0.84 | TTR (0.62) | GALR3HTR4TTRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040092570-A1 | GAL3 antagonists for the treatment of neuropathic pain | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2004-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092570-A1 | GAL3 antagonists for the treatment of neuropathic pain | GALR3, GALR2, GALR1 | GALR3 1/4885HTR4 214/4885TTR 4610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.